Synthimed Labs Private Limited Company Profile,Synthimed Labs Private Limited Essential Information

Company Profile

Our Company Our Business

Year Established : 1995

Total Assets(USD) : 500,000 to 99,999,999

Total Number of Staff : more than 1000

Main Competitive Advantages : International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service

Other Competitive Advantages : Highlights of Our Regulatory Expertise: At our core, we strive for regulatory excellence, ensuring seamless global operations for our partners. With over 30+ successful regulatory audits and 350+ customer audits, we are proud to showcase our compliance journey spanning multiple countries and esteemed regulatory bodies, including the FDA (USA), PMDA (Japan), EMA (Europe), and many more. ✅FDA (USA): Approved for all 15 DMFs submitted, with successful inspections in 2007, 2011, 2015, 2017, 2018, and 2020. ✅PMDA (Japan): Key product approvals like Risedronate Na and Pioglitazone HCL (2010, 2017). ✅Europe: Approval for Clopidogrel and Clarithromycin with successful inspections in 2016. ✅Australia, Germany, and Beyond: Expanding global compliance with inspections from leading authorities, ensuring alignment with pharmaceutical standards. Other Key highlights: • Trusted partner for global pharma giants in 50+ countries • 3 state-of-the-art manufacturing sites with USFDA, ANVISA, and EDQM certifications • Robust R&D center with 160 dedicated scientists • Expertise in 16 therapeutic segments • Strong regulatory compliance with 16 US DMFs, 16 CEPs, and 13 Japan DMFs • Sustainable, Cost-Effective, and Scalable API Solutions

Patents and Copyrights : NB: * Products subject to patent protection are not offered or supplied for commercial purposes in countries where this constitutes an infringement of patent rights. * Products under patent protection are only available pursuant to Section 107-A (a) of the Indian Patents Act 1970.

Business Type : Manufacturer

R&D Capacity : OEM

Annual Turnover(USD) : 500,000 to 99,999,999

Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Product Range : Our Commercial Offerings ranges through various Therapeutic Categories: • Macrolide Antibiotic • Cardiovascular • Antihistamine • Antidiabetic • Antipsyhotic • Bone Resorption Inhibitor • Parkinson’s Disease • Hyperparathyroidism • Aromatase Inhibitor • Nootropic • Antidiarrhoeal / Antiprotozoal • Alcohol Abstinence • Antineoplastic • Anticancer • Antimuscarinic • Thrombocytopenia • Hypercholesterolemia Products Under Developments: • Ivacaftor (Form C & Amorphous) • Tegoprazan (Form A) • Cenobamate • Valganciclovir HCl (Form A) • Sitagliptin HCl • Sitagliptin Phosphate Monohydrate • Vibegron • Vonoprazan Fumarate (Form A) • Bilastine (Form-I) • Valbenazine Tosylate • Bisoprolol Fumarate • Diroximel Fumarate • Vericiguat • Mirogabalin Besylate • Lumateperone Tosylate • Ribociclib • Darolutamide • Pomalidomide • Zanubrutinib • Lercanidipine Hydrochloride • Upadacitinib • Nebivolol • Trimebutine Maleate • Patiromer Sorbitex Calcium • Rimegepant • Mitapivat Sulphate NB: * Products subject to patent protection are not offered or supplied for commercial purposes in countries where this constitutes an infringement of patent rights. * Products under patent protection are only available pursuant to Section 107-A (a) of the Indian Patents Act 1970.

Send Inquiry

Synthimed Labs Private Limited
Contact Person : Anurag Chaturvedi
Tel: Click to View
Fax: India-Delhi-

Synthimed Labs Private Limited is a pioneering pharmaceutical company that has established itself as a leader in the global market. With significant investment in research and development, state-of-the-art manufacturing facilities, and a commitment to quality and innovation, we have earned a reputation for excellence. Our company boasts an impressive array of global accreditations, including US FDA, EU GMP, WHO, EDQM, ANVISA, MFDS among others.

At the heart of our success lies an extensive portfolio of Active Pharmaceutical Ingredients (APIs), comprising high-quality products. Our API portfolio caters to diverse therapeutic areas, such as oncology, cardiovascular, anti-infectives, anti-diabetic, anti histamine, anti psychotics etc with a global dominance in the macrolide antibiotic segment.

We are a champion in manufacturing and exporting APIs viz.,

Clarithromycin

Atorvastatin

Fexofenadine

Clopidogrel Bisulfate

Ezetimibe

Ivabradine

Nitazoxanide

Letrozole

Anastrozole

Ibrutinib

Pazopanib

Cinacalcet

Donepezil

Acamprosate Calcium

Risedronate Sodium ….etc. and have a basket of 34+ APIs across 19 therapeutic categories.

We have a meticulous planning for further introduction of many more new APIs in coming days.

With quality products at competitive price, strong regulatory support, sustainable supply chain capacity and persistent customer service, we are quite hopeful of being your API sourcing partner.

Please provide contact details of the concern person in your API procurement department so that we can write more about our products. However, one can download our Brochure and Product List by going through below link.

https://synthimed.com/apis/

Please stay in touch with us for catering your requirements for APIs.

You are mostly welcome to visit us at our Booth # E2B63 wherein we can get an opportunity to meet and discuss on your requirements for APIs.

Contact:

Anurag Chaturvedi

Sr. Vice President & Head of API Sales & Marketing

Email: anurag.chaturvedi@synthimed.com

Mobile: +91 9810324977

Ekta Sharma

AGM - Sales & Marketing

Email: sharma.ekta@synthimed.com

Mobile: +91 9910900734

Company Profile of Synthimed Labs Private Limited

Company Profile